|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date22 Jul 2005 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
CB275舌下膜在健康参与者中的安全性和药代动力学特征及与对照制剂雷美替胺片相对生物利用度的I期临床研究
[Translation] A Phase I clinical study of the safety and pharmacokinetic characteristics of CB275 sublingual membrane in healthy participants and its relative bioavailability compared to the control formulation ramelteamide tablets.
主要目的是评价健康参与者单次舌下给药CB275舌下膜的药代动力学特征。同时评价健康参与者单次舌下给药CB275舌下膜的安全性、考察单次舌下给药CB275舌下膜及单次口服雷美替胺片的药代动力学特征,评价两制剂间相对生物利用度(F)和评价CB275舌下膜的适口性。
[Translation] The primary objective was to evaluate the pharmacokinetic characteristics of a single sublingual administration of CB275 sublingual film in healthy participants. Simultaneously, the safety of a single sublingual administration of CB275 sublingual film in healthy participants was evaluated, the pharmacokinetic characteristics of a single sublingual administration of CB275 sublingual film and a single oral administration of ramelteamide tablets were investigated, the relative bioavailability (F) between the two formulations was assessed, and the palatability of the CB275 sublingual film was evaluated.
/ Not yet recruitingPhase 1 CB345 膜剂在健康参与者中的安全性和药代动力学特征及与对照制剂阿戈美拉汀片相对生物利用度的 I 期临床研究
[Translation] A Phase I clinical study of the safety and pharmacokinetic characteristics of CB345 film formulation in healthy participants and its relative bioavailability compared to the control formulation agomelatine tablets.
主要目的是评价健康参与者单次给药CB345膜剂的药代动力学特征。同时评价健康参与者单次给药CB345膜剂的安全性、考察单次给药膜剂及单次口服阿戈美拉汀片的药代动力学特征,评价两制剂间相对生物利用度(F),评价口腔不同给药部位对CB345膜剂药代动力学特征的影响和评价CB345膜剂的适口性。
[Translation] The primary objective was to evaluate the pharmacokinetic characteristics of a single-dose CB345 film formulation in healthy participants. Simultaneously, the safety of a single-dose CB345 film formulation in healthy participants was assessed, the pharmacokinetic characteristics of a single-dose film formulation and a single oral agomelatine tablet were examined, the relative bioavailability (F) between the two formulations was evaluated, the impact of different oral administration sites on the pharmacokinetic characteristics of the CB345 film formulation was evaluated, and the palatability of the CB345 film formulation was assessed.
/ Not yet recruitingPhase 2 CB275舌下膜治疗入睡困难的失眠症有效性和安全性的多中心、随机、双盲、阳性药物对照的II期临床研究
[Translation] A multicenter, randomized, double-blind, positive-drug-controlled phase II clinical study to investigate the efficacy and safety of CB275 sublingual membrane in treating insomnia with difficulty falling asleep.
主要目的:评估 CB275 舌下膜治疗入睡困难的失眠症的客观指标有效性。次要目的:评估 CB275 舌下膜治疗入睡困难的失眠症的其他主客观指标的有效性、安全性和药代动力学特征等。
[Translation] Primary objective: To evaluate the objective efficacy of CB275 sublingual membrane in treating insomnia with difficulty falling asleep. Secondary objective: To evaluate the efficacy, safety, and pharmacokinetic characteristics of other subjective and objective indicators of CB275 sublingual membrane in treating insomnia with difficulty falling asleep.
100 Clinical Results associated with Hangzhou Chengbang Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Hangzhou Chengbang Pharmaceutical Technology Co., Ltd.
100 Deals associated with Hangzhou Chengbang Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Hangzhou Chengbang Pharmaceutical Technology Co., Ltd.